Helicobacter pylori infection
Conditions
Interventions
Control group (VT dual group):Vonoprazan 20 mg twice daily + tetracycline 0.5 g three times daily, for a duration of 14 days
Test group (VM dual group):Vonoprazan 20 mg twice daily + minocycline 100 mg twice daily, for a duration of 14 day
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years, no gender restriction; 2. Positive for Helicobacter pylori (indicated by a positive urease breath test and determined by a doctor to require treatment for Helicobacter pylori infection); 3. Allergic to penicillin (including those with a positive penicillin skin test or who have experienced an allergic reaction after using penicillin).
Exclusion criteria
Exclusion criteria: 1. Patients who have previously undergone treatment for Helicobacter pylori; 2. Pregnant or breastfeeding women; 3. Those who have used antibiotics, bismuth agents, or acid suppressants (PPI or P-cab) within 4 weeks prior to treatment; 4. Patients with other serious diseases that could affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumors, or alcoholism; 5. Individuals allergic to the drugs used in this study (vonoprazan fumarate, tetracycline, minocycline) or their components, or who need to use these drugs with caution or are contraindicated due to underlying diseases or concurrent medications; 6. Participants in other drug studies within 3 months prior to using the study drug; 7. Patients who are unable to properly express their complaints, such as those with psychiatric disorders or severe neurosis, and are unable to cooperate with the trial; 8. Other situations that the researcher deems unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Side effects;adherence; | — |
Countries
China
Contacts
Public ContactHong Cheng
Peking University First Hospital
Outcome results
None listed